DYN — Dyne Therapeutics, Inc. stock price, charts and financials

QT76Dyne Therapeutics, Inc.

Dyne Therapeutics, Inc. (NASDAQ: DYN) is a Healthcare company in the Biotechnology industry. QuoTrend tracks its price, financials, earnings, analyst ratings and insider trades.

Latest market price
25.97
+0.73+2.89%
OverviewShort InterestFilings
DYNQT76Dyne Therapeutics, Inc.·NASDAQ
25.97+2.89%
TA
Loading chart...
Signal & projected range
Earnings big miss — drift (PEAD)Historical pattern — not a prediction
Recent priceDays this stock last showed the setupRange of past outcomes (±1σ)
Horizon
0%Past 3 monthsToday
Unlock the projected rangeSee where this setup landed historically — with Premium.
Unlock with Premium

Over the next 20 trading days, similar setups historically landed in a measured range of outcomes. Unlock with Premium to see the median return, the typical range, and how often they were positive. This is the historical range of outcomes — not a prediction of this stock’s price.

Ranges describe how this exact setup resolved in the past — derived from thousands of historical occurrences across QuoTrend’s coverage since 2006, survivorship-corrected to include companies that later delisted. The band is the typical spread (±1σ) of those outcomes, not a forecast; the central value is their average move. Fewer matching cases over longer horizons widen the band and lower its reliability. Backtested results are hypothetical, based on historical data, and do not represent actual trading. Past performance does not guarantee or predict future results. QuoTrend is an educational research tool, not investment advice. Markets involve risk, including loss of principal.

Screen all →
CRSP+7.06%$53.07CAI-1.35%$16.10DFTX+1.27%$42.32DNTH+4.13%$110.40ACAD+6.01%$27.15TVTX+1.89%$56.02CELC+5.44%$92.49MANE+5.29%$107.28
Snapshot
Index-P/E-EPS (ttm)-7.67Insider Own13.78%Shs Outstand186.75MPerf Week-1.52%
Market Cap4.71BForward P/E-EPS next Y-3.26Insider Trans-19.37%Shs Float152.03MPerf Month9.41%
Enterprise Value3.84BPEG-EPS next Q-0.84Inst Own-Short Float14.14%Perf Quarter45.14%
Income-1.24BP/S4.68EPS this Y54.94%Inst Trans-Short Ratio11.51Perf Half Y41.08%
Sales1.01BP/B6.71EPS next Y5.58%ROA-52.25%Short Interest21.49MPerf YTD29.04%
Book/sh3.76P/C5.25EPS next 5Y-ROE-64.30%52W High27.02 -3.88%Perf Year156.24%
Cash/sh4.81P/FCF-EPS past 3/5Y-ROIC-58.28%52W Low9.85 163.74%Perf 3Y135.45%
Dividend Est.-EV/EBITDA15.98Sales past 3/5Y-Gross Margin0.00%Volatility5.56% 5.92%Perf 5Y29.57%
Dividend TTM-EV/Sales3.81EPS Y/Y TTM-127.60%Oper. Margin0.00%ATR (14)1.41Perf 10Y-
Dividend Ex-Date-Quick Ratio12.02Sales Y/Y TTM-Profit Margin0.00%RSI (14)61.97Recom2.07
Dividend Gr. 3/5Y-Current Ratio12.02EPS Q/Q-11.34%SMA204.12%Beta1.09Target Price35.00
Payout0.00%Debt/Eq0.02Sales Q/Q-SMA5018.88%Rel Volume1.01Prev Close25.24
Employees263LT Debt/Eq0.02EarningsNov 04SMA20031.75%Avg Volume2.11MPrice25.97
IPO DateSep 17, 2020Option/ShortYes / YesEPS/Sales Surpr.-44.23% -Net Debt/EBITDA1.32Volume2,131,920Change2.89%
Analyst Ratings
DateActionAnalystRatingTarget
Jul-31-26ReiteratedMorgan StanleyOverweight$47 → $45
May-15-26ReiteratedEvercore ISI GroupOutperform$36 → $33
May-13-26ReiteratedBernsteinMarket Perform$23 → $24
Dec-15-25ReiteratedEvercore ISI GroupOutperform$38 → $36
Dec-11-25ReiteratedStifel Nicolaus$36 → $39
Dec-10-25UpgradeOppenheimerPerform → Outperform$13 → $40
Dec-09-25ReiteratedTudor Pickering$23
Dec-09-25ReiteratedBernstein$21 → $23
Dec-08-25ReiteratedRobert W. Baird$30
Dec-08-25ReiteratedRaymond JamesStrong Buy$35 → $40
Latest News
Jul-29-26
Jul-29-2605:33PM
Dyne Therapeutics Q2 EPS $(1.08) Misses $(0.75) EstimateBenzinga
04:30PM
Dyne Therapeutics Reports Second Quarter 2026 Financial Results and Recent Business Highlightsglobenewswire.com
Jul-28-26
Jul-28-2607:30AM
Dyne Therapeutics Announces U.S. FDA Clearance of Investigational New Drug (IND) Application for DYNE-302 in Facioscapulohumeral Muscular Dystrophy (FSHD)globenewswire.com
Jul-27-26
Jul-27-2604:03AM
Fifth Third Bancorp Buys New Shares in Dyne Therapeutics, Inc. $DYNdefenseworld.net
Jul-24-26
Jul-24-2604:05PM
Dyne Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)globenewswire.com
Jul-23-26
Jul-23-2604:05PM
Dyne Therapeutics Announces Closing of Upsized Public Offering of Common Stock and Full Exercise by Underwriters of Option to Purchase Additional Sharesglobenewswire.com
09:49AM
Cantor Fitzgerald Initiates Coverage On Dyne Therapeutics with Overweight RatingBenzinga
Jul-21-26
Jul-21-2610:46PM
Dyne Therapeutics Announces Pricing of Upsized $375 Million Public Offering of Common Stockglobenewswire.com
05:05PM
12 Health Care Stocks Moving In Tuesday's After-Market SessionBenzinga
04:46PM
Dyne Therapeutics Announces Proposed Public Offering of Common Stockglobenewswire.com
11:20AM
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?zacks.com
Jul-20-26
Jul-20-2602:35PM
Dyne Therapeutics: A Buy, With Caveats, On DMD Progressseekingalpha.com
07:30AM
Dyne Therapeutics Announces U.S. FDA Acceptance of Biologics License Application (BLA) for Z-Rostudirsen in Exon 51 Duchenne Muscular Dystrophy (DMD)globenewswire.com
Jul-04-26
Jul-04-2609:21AM
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?fool.com
Jul-01-26
Jul-01-2611:38AM
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?fool.com
Company

Dyne Therapeutics, Inc. is a U.S.-based biotechnology firm focused on developing advanced treatments for genetically driven muscle disorders. Utilizing its proprietary FORCE platform, which is engineered to deliver disease-modifying therapeutics, the company is actively engaged in various programs. These initiatives target conditions such as myotonic dystrophy type 1, Duchenne muscular dystrophy, and facioscapulohumeral dystrophy, in addition to other rare skeletal, cardiac, and metabolic muscle diseases. The company was founded in 2017 and maintains its corporate headquarters in Waltham, Massachusetts.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue
1,00800000000
Cost of Goods Sold Incl. D&A2,93222200100
Gross Profit-1,924-2-2-200-100
Selling, General and Administrative Excl. Other18970623128291331
Research and Development039828121114312145114
Other Operating Expense0-2-1-200000
Operating Income-438-468-344-242-171-150-59-14-5
Interest Expense61660030000
Unusual Expense
—————————
Non-Operating Income (Expense)-23528266610-10
Net Income Before Taxes-1,289-446-317-236-168-149-59-15-5
Income Taxes-66000000-100
Consolidated Net Income-1,243-446-317-236-168-149-59-14-5
Net Income From Continuing Operations-1,243-446-317-236-168-149-59-15-5
Net Income-1,243-446-317-236-168-149-59-14-5
EPS (Recurring)-7.67-3.47-3.37-3.95-3.23-2.93-1.24-0.30-0.47
EPS (Basic, Before Extraordinaries)-7.67-3.47-3.37-3.95-3.23-2.93-1.24-0.30-0.47
EPS (Diluted)-7.67-3.47-3.37-3.95-3.23-2.93-1.24-0.30-0.47
EBITDA240-438-315-233-163-148-58-15-5
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio
—————————
Price To Sales Ratio
4.17————————
Gross Margin
-190.87————————
Operating Margin
-43.45————————
Net Margin
-123.31————————
Shares Outstanding16212894605251474510
Market Capitalization4,2072,5042,215798603606987——
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$28.64$22.86$17.07$11.29$5.51● Close Price0.00M9.23M18.46M27.69M36.93MUSD Trades VolumeAugSepOctNovDec2026FebMarAprMayJunJulAug
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
Kersten DirkDirectorJul 27 '26Sale25.51261,4606,670,7703,586,796Jul 29
Rhodes Jason PDirectorJul 07 '26Sale23.26297,2116,913,8212,962Jul 08
Rhodes Jason PDirectorJul 06 '26Sale22.79480,24010,944,670875,912Jul 08
Rhodes Jason PDirectorJun 29 '26Sale21.14195,4274,131,327975,931Jun 30
Rhodes Jason PDirectorJun 26 '26Sale21.28309,2686,581,2231,016,633Jun 30
Rhodes Jason PDirectorJun 25 '26Sale21.1024,100508,5101,081,044Jun 26
Lucera ErickChief Financial OfficerJun 25 '26Sale20.372,36248,114121,563Jun 26
Rhodes Jason PDirectorJun 24 '26Sale21.0295,9002,015,8181,086,063Jun 26
Rhodes Jason PDirectorJun 23 '26Sale21.13147,7603,122,1691,106,036Jun 26
Kersten DirkDirectorJun 23 '26Sale21.0573,2861,542,3493,848,256Jun 24
Kersten DirkDirectorJun 22 '26Sale20.57190,6763,922,2633,921,542Jun 24
Kersten DirkDirectorJun 18 '26Sale20.0746,901941,3734,112,218Jun 22
Kersten DirkDirectorJun 17 '26Sale20.1437,454754,3164,159,119Jun 22
Kerr DouglasChief Medical OfficerJun 16 '26Sale18.3388716,259169,155Jun 17
Friedl-Naderer JohannaChief Commercial OfficerJun 16 '26Sale18.331452,658154,208Jun 17
open in yahoo·open in reuters·open in marketwatch·open in google·open in EDGAR
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.